US › Healthcare

Cybin Inc. Common Stock (HELP)

US · Healthcare · Biotechnology

$9.28+15.14%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.3M
Net profit
$-47.0M
Profit YoY
-53.7%
EPS
$-0.93
EPS estimate
$-0.80
Net margin
-3,617.8%

EPS came in at -0.93 against a street estimate of -0.80 — a miss of 16.8%.

Key statistics

Market cap
$499.6M
Forward P/E
0.0
P/B
2.09
Book value
$0.05
EPS (TTM)
$-4.25
52-week high
$9.40
52-week low
$3.76
50-day MA
$5.77
200-day MA
$6.09
Beta
0.56

Analyst view

with an average price target of $35.26.

Shareholding

Insiders
2.75%
Institutions
39.13%

Largest institutional holders

FundStake
VR Adviser, LLC6.21%
Orbimed Advisors, LLC6.18%
Millennium Management LLC3.90%
Rosalind Advisors, Inc.2.47%
Eventide Asset Management, LLC2.28%
Deep Track Capital, LP2.12%
Morgan Stanley - Brokerage Accounts1.65%
Sphera Funds Management Ltd.1.59%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cybin Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.